Global Neurodegenerative Disease Market 2022-2028

December 2022 | 78 pages | ID: GEBAB0A584B3EN
Gen Consulting Company

Abstracts

The global neurodegenerative disease market is likely to register a CAGR of over 3.2% with an incremental growth of USD 7.1 billion during the forecast period 2022-2028.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global neurodegenerative disease market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the neurodegenerative disease industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the indication, drug, and region. The global market for neurodegenerative disease can be segmented by indication: Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, others. Among these, the multiple sclerosis segment was accounted for the highest revenue generator in 2021. Neurodegenerative disease market is further segmented by drug: N-methyl-D-aspartate receptor antagonist, cholinesterase inhibitor, dopamine agonist, immunomodulatory drug, others. The immunomodulatory drug segment is estimated to account for the largest share of the global neurodegenerative disease market. Based on region, the neurodegenerative disease market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the largest share of the global neurodegenerative disease market in 2021 and is anticipated to hold its share during the forecast period.

Market Segmentation

By indication: Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, others

By drug: N-methyl-D-aspartate receptor antagonist, cholinesterase inhibitor, dopamine agonist, immunomodulatory drug, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The market research report covers the analysis of key stake holders of the global neurodegenerative disease market. Some of the leading players profiled in the report include Abbvie Inc., Amneal Pharmaceuticals Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Teva Pharmaceuticals Ltd., UCB S.A., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global neurodegenerative disease market.
• To classify and forecast the global neurodegenerative disease market based on indication, drug, region.
• To identify drivers and challenges for the global neurodegenerative disease market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global neurodegenerative disease market.
• To identify and analyze the profile of leading players operating in the global neurodegenerative disease market.

Why Choose This Report

• Gain a reliable outlook of the global neurodegenerative disease market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY INDICATION

Parkinson's disease
Alzheimer's disease
Multiple sclerosis
Huntington's disease
Others

PART 6. MARKET BREAKDOWN BY DRUG

N-methyl-D-aspartate receptor antagonist
Cholinesterase inhibitor
Dopamine agonist
Immunomodulatory drug
Others

PART 7. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 8. KEY COMPANIES

Abbvie Inc.
Amneal Pharmaceuticals Inc.
Biogen Inc.
Boehringer Ingelheim International GmbH
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Teva Pharmaceuticals Ltd.
UCB S.A.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER